Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04480125 | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | unknown | Phase 2 | 28 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05322733 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | unknown | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05286164 | Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | unknown | Phase 2 | 30 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05320081 | Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma | unknown | Phase 2 | 30 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04246359 | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma(RIPPLE) | unknown | Phase 2 | 52 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05093140 | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL(CREDIT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05147493 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | unknown | Phase 2 | 51 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05298683 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | unknown | Phase 2 | 108 | Hellenic Society of HematologyOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05290337 | ZR-CHOP in DLBCL With Specific Gene Abnormality | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma(ZR2-CHOP) | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05186558 | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | unknown | Phase 2 | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT02776605 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia(PONALFIL) | unknown | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Feb 14, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05179213 | Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05149170 | Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05076097 | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | unknown | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT03505944 | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma(VALERIA) | unknown | Phase 1 / Phase 2 | 59 | Nordic Lymphoma GroupNETWORK | 4 | Oct 13, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT04948788 | SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 102 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05059912 | CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03439501 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | unknown | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05049473 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | unknown | Phase 2 | 100 | PETHEMA FoundationOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT05006664 | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | unknown | Phase 2 | 33 | Czech Lymphoma Study GroupOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT05014100 | Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma | unknown | Phase 2 | 55 | Puyang Oilfield General HospitalOTHER | 0 | Aug 27, 2021 | clinicaltrials |
| NCT04736914 | Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04610970 | A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） | unknown | Phase 2 | 93 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | unknown | Phase 2 / Phase 3 | 60 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT04866654 | Radiation Free Chemotherapy for Early Hodgkin Lymphoma(RAFTING) | unknown | Phase 2 | 160 | Medical University of GdanskOTHER | 3 | Aug 12, 2021 | clinicaltrials |
| NCT04994626 | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 6, 2021 | clinicaltrials |
| NCT00324467 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment(LYTPET) | unknown | Phase 2 | 150 | British Columbia Cancer AgencyOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04129710 | A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT04938297 | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | unknown | Phase 2 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 24, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 20, 2022source: clinicaltrials